Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMV

IMV (IMV) Stock Price, News & Analysis

IMV logo

About IMV Stock (NASDAQ:IMV)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.49
$0.91
52-Week Range
N/A
Volume
44,800 shs
Average Volume
233,607 shs
Market Capitalization
$9.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

Receive IMV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

IMV Stock News Headlines

Is This The Next Toyota FJ Cruiser?
Why Wall Street Is Quietly Loading Up Ahead of Tesla’s Austin Breakout
In the next few days, Elon Musk could trigger the biggest wealth shift in a generation. And two of Wall Street’s sharpest minds – Cathie Wood and Dan Ives – are already positioning themselves ahead of the announcement. Why? Because what’s about to launch in Austin isn’t just a new product… It’s the starting gun for a $34 trillion wealth event tied to autonomous vehicles, AI, and Musk’s newest innovation.
See More Headlines

IMV Stock Analysis - Frequently Asked Questions

IMV Inc. (NASDAQ:IMV) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($1.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.30). The business had revenue of $0.04 million for the quarter. IMV had a negative net margin of 11,547.42% and a negative trailing twelve-month return on equity of 12,695.41%.

IMV's stock reverse split before market open on Tuesday, December 13th 2022. The 1-10 reverse split was announced on Tuesday, December 13th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that IMV investors own include Pfizer (PFE), Nokia (NOK), NIO (NIO), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), VBI Vaccines (VBIV) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
11/11/2021
Today
6/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMV
Fax
N/A
Employees
97
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.99 million
Net Margins
-11,547.42%
Pretax Margin
-11,547.42%
Return on Equity
-12,695.41%

Debt

Sales & Book Value

Annual Sales
$330 thousand
Price / Cash Flow
N/A
Book Value
($0.69) per share
Price / Book
N/A

Miscellaneous

Free Float
11,673,000
Market Cap
$9.63 million
Optionable
Optionable
Beta
0.95
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:IMV) was last updated on 6/18/2025 by MarketBeat.com Staff
From Our Partners